CRISPR Therapeutics AG (CRSP) Total Current Liabilities (2015 - 2026)

CRISPR Therapeutics AG has disclosed Total Current Liabilities across 12 years of filings, most recently posting $132.9 million for Q2 2026.

• In Q2 2026, Total Current Liabilities rose 27.34% year-over-year to $132.9 million; the TTM figure through Jun 2026 stood at $132.9 million (up 27.34% YoY), while the FY2025 annual figure was $149.1 million, up 69.88% from the prior year.
• Total Current Liabilities came in at $132.9 million for Q2 2026 at CRISPR Therapeutics AG, down from $136.3 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $150.9 million in Q3 2022 to a low of $87.8 million in Q4 2024.
• Average Total Current Liabilities over 5 years is $121.7 million, with a median of $119.7 million recorded in 2022.
• Year-over-year, Total Current Liabilities dropped 26.27% in 2023 and surged 69.88% in 2025.
• Over 5 years, Total Current Liabilities stood at $121.1 million in 2022, then dropped by 10.17% to $108.8 million in 2023, then retreated by 19.31% to $87.8 million in 2024, then surged by 69.88% to $149.1 million in 2025, then decreased by 10.88% to $132.9 million in 2026.
• Per Business Quant data, the three most recent Total Current Liabilities figures were $132.9 million in Q2 2026, $136.3 million in Q1 2026, and $149.1 million in Q4 2025.